High-dose epirubicin and cisplatin in locally advanced undifferentiated nasopharyngeal carcinoma

Clinical Oncology

Volumn 14, Issue 6, 2002, Pages 449-454

  Onat, H ^a   Basaran, M ^a   Esassolak, M ^b   Bavbek, S E ^a   Anacakt, Y ^b   Kaytan, E ^a   Altun, M ^a   Haydaroglu, A ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b EGE UNIVERSITY   (Turkey)

Author keywords

Cisplatin; Epidoxorubicin; Locally advanced; Nasopharyngeal cancer; Neoadjuvant chemotherapy

Indexed keywords

BLEOMYCIN; CISPLATIN; EPIRUBICIN;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; COBALT THERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TOXICITY TESTING; TREATMENT OUTCOME; UNDIFFERENTIATED CARCINOMA;

EID: 0036895132     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2002.0110     Document Type: Article

References (22)

1. Fandi A, Altun M, Azli N, et al. Nasopharyngeal cancer epidemiology, staging and treatment. Semin Oncol 1994;42:382-397.
2. Altun M, Fandi A, Dupuis O, et al. Undifferentiated nasopharyngeal cancer (UNCT). Current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys 1995;32:859-877.
3. Baker SR, Wolfe RA. Prognostic factors of nasopharyngeal malignancy. Cancer 1982;49:163-169.
4. Laramore GE, Clubb B, Quick C, et al. Nasopharyngeal carcinoma in Saudi Arabia: a retrospective study of 166 cases treated with curative intent. Int J Radiat Oncol Bio Phys 1988;15: 1119-1127.
5. Teo P, Tsao SY, Shiv W, et al. A clinical study of 407 cases of nasopharyngeal carcinoma in Hong Kong. Int J Radiat Oncol Bio Phys 1989;17:515-530.
6. Lee AWM, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992;23:261-270.
7. Boussen H, Cvitkovic E, Wendling JI, et al. Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin and fluorouracil. J Clin Oncol 1991;9:1675-1681.
8. Choo R, Tannock I. Chemotherapy for recurrent and metastatic carcinoma of nasopharynx. Cancer 1991;68:1220 1224.
9. Gebbia V, Zeriilo G, Restivo G, et al. Chemotherapeutic treatment of recurrent and/or metastatic nasopharyngeal carcinoma: a retrospective analysis of 40 cases. Br J Cancer 1993;68:191-194.
10. Huang SC, Lui LT, Lynn TS, et al. Nasopharyngeal cancer: Study III. A review of 1206 patients treated with combined modalities. Int J Radiat Oncol Biol Phys 1985;11:1789-1793.
11. Bachouchi M, Cvitkovic E, Azli N, et al. High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin and cisplatin before radiotherapy. J Natl Cancer Inst 1990;82:616-620.
12. Azli N, Armand JP, Rahal M, et al. Alternating chemoradiotherapy with cisplatin and 5-fluorouracil plus bleomycin by continuous infusion for locally advanced undifferentiated carcinoma of nasopharyngeal type. Eur J Cancer 1992;28A: 1792-1797.
13. Onat H, Altun M, Bilge N, et al. Neoadjuvant chemotherapy and radiotherapy in locally advanced undifferentiated nasopharyngeal carcinoma. J Exp Clin Cancer Res 1992;11:203-206.
14. Dimery I, Peters LJ, Geopfert H, et al. Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma. J Clin Oncol 1993;11:1919-1928.
15. Zidan J, Kuten A, Robinson E. Intensive short course chemotherapy followed by radiotherapy of locally advanced nasopharyngeal carcinoma. Cancer 1996;77:1973-1977.
16. International Nasopharynx Cancer Study Group. VUMCA 1 Trial: Preliminary results of a randomized trail comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (≥N2,M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys 1996;35:463-469.
17. Chua DTT, Sham JST, Choy D, et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Cancer 1998;83:2270-2283.
18. Ma J, Mai H, Hong M, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001;19:1350-1357.
19. Al-Sarraf M, LeBlanc M, Giri PGS, et al. Chemo-radiotherapy (CT-RT) vs radiotherapy (RT) in patients (Pts) with advanced nasopharyngeal cancer (NPC). Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388). J Clin Oncol 1998;16:1310-1317.
20. Peters LJ, Harrison ML, Dimery IW. Acute and late toxicity associated with sequential bleomycin containing chemotherapy in the treatment of carcinoma of nasopharnx. Int J Radiat Oncol Biol Phys 1988;14:623-633.
21. El Gueddari B, on behalf of the International Nasopharynx Cancer Study Group. Final results of the VUMCA I randomized trial comparing neoadjuvant chemotherapy (CT) (BEC) plus radiotherapy (RT) to RT alone in undifferentiated nasopharyngeal carcinoma (UCNT). Proc Am Soc Clin Oncol 1998;17: abstr 1482.
22. Cvitkovic E. UNCT: Chemocurable sometimes, but not very often. Ann Oncol 1997;8:723-735.